Virtu Financial’s Trinity Biotech TRIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-889
Closed -$14K 2253
2026
Q1
$14K Buy
+889
New +$19.6K ﹤0.01% 1431
2024
Q4
Sell
-593
Closed -$20K 2062
2024
Q3
$20K Buy
593
+117
+25% +$7.91K ﹤0.01% 1129
2024
Q2
$30K Buy
+476
New +$27.7K ﹤0.01% 981
2023
Q1
Sell
-83
Closed -$12K 2104
2022
Q4
$12K Sell
83
-15
-15% -$2.73K ﹤0.01% 1358
2022
Q3
$16K Buy
+98
New +$19K ﹤0.01% 1450
2022
Q2
Sell
-253
Closed -$40K 2081
2022
Q1
$40K Buy
+253
New +$43.7K ﹤0.01% 1185
2021
Q1
Sell
-199
Closed -$114K 2026
2020
Q4
$114K Buy
199
+29
+17% +$14.4K 0.01% 1025
2020
Q3
$51K Buy
+170
New +$59K 0.01% 821
2018
Q4
Sell
-225
Closed -$135K 1990
2018
Q3
$135K Buy
+225
New +$147K 0.01% 1149

Other funds holding TRIB

Virtu Financial's TRIB Position: Q2 2026 in Review

Virtu Financial sold out of Trinity Biotech (TRIB) in Q2 2026, closing a stake of 889 shares — an estimated $14K sold.

Virtu Financial first reported a position in TRIB in Q3 2018 and held it in 9 quarters. The position peaked at $135K in Q3 2018. 19 funds tracked by Wall St. Rank hold TRIB as of Q2 2026.

  • Virtu Financial reported no remaining Trinity Biotech position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 889 Trinity Biotech shares in Q2 2026, an estimated $14K.
  • Virtu Financial first reported a position in Trinity Biotech in Q3 2018 and held it in 9 quarters.
  • Virtu Financial's Trinity Biotech position peaked at $135K in Q3 2018.
  • 19 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.